Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregor Novak

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Best Practice & Research. Clinical Gastroenterology|August 1, 2018
Can we move directly from 5-ASA to a biologic agent in ulcerative colitis?Pieter Hindryckx, Gregor Novak
Cell Biology Education|November 1, 2011
Just-in-Time Teaching in biology: creating an active learner classroom using the InternetKathleen A Marrs, Gregor Novak
Scandinavian Journal of Gastroenterology|December 8, 2025
High persistence and efficacy of ustekinumab as a first-line biological therapy in inflammatory bowel disease: a real-world cohort studyŽiva Šubic, David Drobne, Gregor Novak
United European Gastroenterology Journal|August 1, 2020
Young GI angle: International research fellowship as a way to foster clinical research at your department - our storiesAleksandar Gavric, David Drobne, Gregor Novak
ACG Case Reports Journal|May 17, 2021
Acute Esophageal Necrosis as a Cause of Pneumomediastinum in a Patient With Diabetic KetoacidosisAleksandar Gavric, Samo Plut, Rok Dezman, et al.
Expert Review of Gastroenterology & Hepatology|January 19, 2017
Disease-related and drug-induced skin manifestations in inflammatory bowel diseasePieter Hindryckx, Gregor Novak, Antonio Costanzo, et al.
European Journal of Gastroenterology & Hepatology|March 11, 2026
Applicator preferences for subcutaneous biologics in inflammatory bowel disease: influence on patient satisfaction and willingness to switch treatmentDušica Prodanova, Ana Janeva, David Drobne, et al.
Expert Opinion on Drug Safety|March 10, 2017
The safety of vedolizumab for the treatment of ulcerative colitisGregor Novak, Pieter Hindryckx, Reena Khanna, et al.
Clinical Pharmacology and Therapeutics|July 13, 2017
Infection Risk With Biologic Therapy in Patients With Inflammatory Bowel DiseasePieter Hindryckx, Gregor Novak, Stefanos Bonovas, et al.
European Journal of Gastroenterology & Hepatology|February 19, 2025
First-line anti-TNF agents, ustekinumab and vedolizumab perform similarly in Crohn' disease, but not in ulcerative colitisEva Supovec, Jurij Hanžel, Gregor Novak, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Best Practice & Research. Clinical Gastroenterology|August 1, 2018
Can we move directly from 5-ASA to a biologic agent in ulcerative colitis?Pieter Hindryckx, Gregor Novak
Cell Biology Education|November 1, 2011
Just-in-Time Teaching in biology: creating an active learner classroom using the InternetKathleen A Marrs, Gregor Novak
Scandinavian Journal of Gastroenterology|December 8, 2025
High persistence and efficacy of ustekinumab as a first-line biological therapy in inflammatory bowel disease: a real-world cohort studyŽiva Šubic, David Drobne, Gregor Novak
United European Gastroenterology Journal|August 1, 2020
Young GI angle: International research fellowship as a way to foster clinical research at your department - our storiesAleksandar Gavric, David Drobne, Gregor Novak
ACG Case Reports Journal|May 17, 2021
Acute Esophageal Necrosis as a Cause of Pneumomediastinum in a Patient With Diabetic KetoacidosisAleksandar Gavric, Samo Plut, Rok Dezman, et al.
Expert Review of Gastroenterology & Hepatology|January 19, 2017
Disease-related and drug-induced skin manifestations in inflammatory bowel diseasePieter Hindryckx, Gregor Novak, Antonio Costanzo, et al.
European Journal of Gastroenterology & Hepatology|March 11, 2026
Applicator preferences for subcutaneous biologics in inflammatory bowel disease: influence on patient satisfaction and willingness to switch treatmentDušica Prodanova, Ana Janeva, David Drobne, et al.
Expert Opinion on Drug Safety|March 10, 2017
The safety of vedolizumab for the treatment of ulcerative colitisGregor Novak, Pieter Hindryckx, Reena Khanna, et al.
Clinical Pharmacology and Therapeutics|July 13, 2017
Infection Risk With Biologic Therapy in Patients With Inflammatory Bowel DiseasePieter Hindryckx, Gregor Novak, Stefanos Bonovas, et al.
European Journal of Gastroenterology & Hepatology|February 19, 2025
First-line anti-TNF agents, ustekinumab and vedolizumab perform similarly in Crohn' disease, but not in ulcerative colitisEva Supovec, Jurij Hanžel, Gregor Novak, et al.
Pageof 3